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Summary 
Fludarabine is a purine analogue that has demonstrated significant activity in B-cell 
malignancies, including chronic lymphocytic leukemia. Fludrabine also possesses an 
immunosuppressive effect and is being used to prevent graft versus host disease 
(GVHD) in the hematopoietc stem cell transplantation. However, the molecular 
mechanism by which fludarabine inhibits immunoreaction remains to be fully 
elucidated. This study found that fludarabine inhibited tumor necrosis factor α 
(TNF-α)-stimulated degradation of IκBα, resulting in blockade of nuclear translocation 
of nuclear factor κB (NF-κB) in Jurkat T-cells, as measured by Western blot analysis, as 
well as immunocytochemistry. The ability of fludarabine to inhibit NF-κB was further 
confirmed by electrophoretic mobility shift assay. We also found that fludarabine 
induced growth arrest and apoptosis of alloreactive as well as TNF-α-stimulated 
peripheral blood mononuclear cells (PBMCs). In addition, fludarabine inhibited 
TNF-α-stimulated production of IL-2 and IFN-γ, which play important roles in onset of 
GVHD, in Jurkat cells. Taken together, fludarabine is useful for management of immune 
disease including GVHD via inactivation of NF-κB.
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Introduction 
Fludarabine is a purine analogue that has demonstrated significant activity in 
B-cell malignancies, including chronic lymphocytic leukemia and indolent 
non-Hodgkin’s lymphoma.1 Fludarabine is converted intracellularly into its active 
metabolite F-ara-ATP, which inhibits DNA as well as RNA synthesis, resulting in 
induction of growth arrest and apoptosis of malignant B-cells.2 Also, fludarabine has 
been included in conditioning regimens for stem cell transplantation because of its 
immnunosuppressive effect, 3 although the mechanisms by which fludarabine inhibits 
T-cell function remain to be fully elucidated. 
Nuclear factor κB (NF-κB) is a transcription factor that regulates expression of 
various genes involved in cell cycle regulation and inhibition of apoptosis, as well as, 
genes involved in inflammatory and immune responses. 4-6 We previously showed that 
inactivation of NF-κB by eight herbal mixture PC-SPES successfully rescued mice from 
LPS-induced septic shock in association with decreased production of inflammatory 
cytokines.7  
GVHD is initiated by tissue damage caused by conditioning regimen which 
consists of chemotherapy and radiotherapy, resulting in release of proinflammatory 
cytokines including IL-1β and TNF-α.8-10 Donor T-cell recognition of host alloantigens 
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activates T-cells and further stimulates cytokine production.11- 13 Released cytokines 
recruits secondary effectors such as macrophages and NK cells to the target organs, 
especially to gastrointestinal tract, which damage tissues, resulting in the leak of 
endotoxin across damaged mucosal barriers, further exacerbating the cytokine cascade. 
These events destruct tissues and causes, in some cases, death.   
This study explored the medicinal action of fludarabine as an 
immunosuppressive agent and found that it possessed anti-NF-κB activity.  
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Materials and Methods.  
Cells. PBMCs were isolated from heparinized blood by density gradient centrifugation 
using Ficoll-Conray. PBMCs were suspended in standard RPMI 1640 medium (Sigma, 
St Louis, MO, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
and incubated in six-well culture plates (Costar, NY, USA) for 2 h at 37 °C with 5% 
CO2. The acute lymphoblastic T-cell leukemia Jurkat cells were cultured in standard 
RPMI 1640 medium (Sigma) supplemented with 10% FBS. 
Chemical. Fludarabine phosphate or cytarabine was provided by Schering AG (Berlin, 
Germany) or Nihon Shinyaku Co. Ltd (Tokyo, Japan), respectively. TNF-α was 
purchased from Sigma Chemical, Co. (St Louis, MO, USA). 
Western blot analysis. Western blot analysis was performed as described previously (7) 
Anti- IκBα (Imgenex, San Diego, CA), anti-phospho- IκBα, anti-cleaved PARP (Cell 
Signaling, Beverly, MA), anti-p65 subunit of NF- κB (Santa Cruz Biotechnology, Santa 
Cruz, CA), and anti-α-tubulin (Santa Cruz Biotechnology) antibodies were used. 
Immunocytochemistry. Jurkat cells were cultured either with or without fludarabine 
(2.5 μM) for 3 hrs and then exposed to TNF-α (20 ng/ml). After 15 min, cells were 
harvested and cytocentrifuge slides were prepared. Anti-p65 (Santa Cruz 
Biotechnology) and anti-mouse IgG antibodies (Amersham Corp., CA, USA) were used 
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for immunocytochemistry. Immune complexes were visualized using the LSAB2 system 
(Dako, Corp., Carpinteria, CA). Sections were counterstained with hematoxylin and 
mounted. 
MTT assays. The effect of fludarabine on proliferation of PBMCs was assessed by 
measuring the mitochondrial-dependent conversion of the 
3-(4,5-dimethylithiazol-2-yl)-2,5-diphenyl tetrazolium salt (MTT) (Sigma), to a colored 
formazan product. PBMCs (4 x 106/ml) were placed in 96-well plates (Flow 
Laboratories, Irvine, CA) and cultured in the following conditions in the presence or 
absence of various concentrations of fludarabine (0.5-5 μM) for 3 days. (1) Culture 
medium alone (control); (2) culture medium plus phytohemagglutinin (5 μg/ml) or 
TNF-α (20 ng/ml); (3) culture medium plus irradiated (3 Gy) allogenic PBMCs (4 x 
106/ml). All experiments were done in triplicate and repeated at least three times. 
Electrophoretic mobility shift assay. Electrophoretic mobility shift assay was done as 
previously described.7 Briefly, 4 μg unclear extracts were incubated with 16 fmol 
32P-end labeled, NF-κB binding probe. The DNA-protein complex was separated from 
the free oligonucleotide on a 5 % polyacrylamide gel. Gels were dried and exposed to 
Kodak XAR film (Eastman Kodak, New Haven, CT). 
Assessment of apoptosis. TNF-α (20 ng/ml)-stimulated PBMCs (1 x 106 cells/ml) were 
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place in 12-well plates and cultured with/without fludarabine (0.5-5 μM). After 24 hrs, 
apoptosis was evaluated by annexin V staining.   
RNA isolation and reverse transcription-polymerase chain reaction. RNA isolation 
and cDNA preparation were performed as described previously.14 We measured 
expression of 18S for normalization as previously described.14 Real-time PCR was 
carried out by using Power SYBR Green PCR Master Mix (Applied Biosystems, 
Warrington, UK) as described previously. 14 Primers for PCR are shown in Table 1. PCR 
conditions for all genes were as follows: 95°C initial activation for 10 minutes followed 
by 45 cycles of 95°C for 15 s and 60°C for 30 s, and fluorescence determination at the 
melting temperature of the product for 20 seconds on an ABI PRISM 7000 (Applied 
Biosystems).  
Statistical analysis. To assess the difference between two groups under multiple 
conditions, one-way ANOVA followed by Boneferroni’s multiple comparison tests were 
performed using PRISM statistical analysis software (GraphPad Software, Inc., San 
Diego, CA).
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Results 
Effect of fludarabine on TNF-α- induced phosphorylation and degradation of IκBα 
and nuclear translocation of NF-κB (p65) in Jurkat cells. In resting T cells, NF-κB 
proteins are sequestered in the cytoplasm as latent precursors by IκBα.15 Upon 
phosphorylation at Ser32 and Ser36 residues, IκBα undergoes degradation by the 26S 
proteasome, resulting in release of NF-κB, leading to nuclear translocation and binding 
to a specific consensus sequence in the DNA. To investigate whether fludarabine 
inhibits TNF-α-stimulated NF-κB activity in jurkat cells, control and fludarabin-treated 
Jurkat cells were exposed to TNF-α (20 ng/ml) for various durations and the kinetics of 
IκBα phosphorylation and degradation were studied by Western blot analysis using 
cytoplasmic extracts (Figure 1a). As shown in Figure 1a, no significant difference in 
pattern of IκBα phosphorylation was observed, but the levels of IκBα were higher in 
fludarabin-treated Jurkat cells than those in control cells, suggesting that fludarabin 
prevented TNF-α-stimulated degradation of IκBα in Jurkat cells. We next examined the 
levels of NF-κB in nucleus in these cells. TNF-α (20 ng/ml, 0-60 min) stimulated 
accumulation of NF-κB in nucleus in both of control and fludarabine-treated cells; 
however, levels of NF-κB were significantly lower in fludarabin-treated cells (Figure 
1b). The ability of fludarabine to inhibit TNF-α-stimulated nuclear translocation of 
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NF-κB was further comfirmed by immunocytochemistry (Figure 1c). One the other 
hand, another nucleoside analogue cytarabine did not affect TNF-α-stumulated nuclear 
translocation of NF-kB in Jurkat cells (Figure 1c). 
Effect of fludarabine on NF-kB activity in Jurkat cells. We next examined whether 
fludarabine affected NF-κB activity in Jurkat cells by utilizing electrophoretic mobility 
shift assay (Figure 2). Exposure of Jurkat cells to TNF-α stimulated NF-kB/DNA 
binding (Figure 2). Pre-incubation of Jurkat cells with fludarabine (2.5 mM, 60 min) 
disrupted formation of TNF-α-stimulated NF-kB/DNA binding complex (Figure 2). The 
NF-kB/DNA complex was competed with 100 times molar excess of unlabeled 
oligonucleotides but not with the same molar excess of mutated oligonucleotides, 
confirming the specificity of NF-κB binding (Figure 2). 
Fludarabine inhibits proliferation of TNF-α-, PHA-, and alloantigen- activated 
PBMCs cells. NF-κB is activated by extracellular signals including TNF-α 16, 17 and 
PHA, 18 and regulates proliferation of activated T lymphocytes.18 We therefore 
examined whether fludarabine affected proliferation of T lymphocytes. Either TNF-α 
(20 ng/ml) or PHA (5 μg/ml) stimulated proliferation of PBMCs from healthy 
volunteers (n=3) by 1.25- and 2.5-fold, respectively, on the third day of culture, as 
measured by MTT assay. (Figures 3a, b). Exposure of these cells to fludarabine (0.5-5 
Nishioka, et al. 
 10
μM) significantly inhibited their proliferation. Likewise, irradiated (3 Gy) allogeneic 
PBMCs stimulated proliferation of normal PBMCs by 2-fold, and fludarabine 
effectively blocked alloreactive expansion of PBMCs (Figure 3c). On the other hand, 
fludarabine did not affect viability of the resting PBMCs (Figures 3a-c). Control studies 
found that cytarabine also inhibited proliferation of TNF-α or PHA-stimulated, but not 
resting PBMCs (Figures 3d, e).    
Fludarabine induces apoptosis of TNF-α-activated T cells. To investigate the 
mechanism by which fludarabine inhibits the proliferation of activated PBMCs, we 
utilized annexin V staining. PBMCs from healthy volunteers were cultured in the 
presence of TNF-α (20 ng/ml) either with or without fludarabine. After 24 h, apoptosis 
was assessed by Annexin V binding and propidium iodide (PI) staining using FACSCan. 
As shown in Figure 4, fludarabine (0.5-5 μM, 24 h) induced approximately 26 % of 
TNF-α-activated PBMCs to become Annexin +/PI -, a feature characteristic of 
apoptosis (Figure 4a). On the other hand, approximately 14 % of control cells became 
apoptotic after 24 h (Figure 4a). In addition, Western blot analysis showed that exposure 
of PBMCs to fludarabine (2.5 or 5 μM, 24 h) induced cleavage of PARP, which is 
thought to be a late event in apoptosis, in TNF-α-stimulated PBMCs, confirming the 
ability of fludarabine to induce apoptosis (Figure 4b).  
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Effect of fludarabine on TNF-α-stimulated cytokine production. Furthermore, we 
studied whether fludarabine affected TNF-α-stimulated production of proinflammatory 
cytokines in Jurkat cells and PBMCs. Exposure of Jurkat cells to TNF-α (20 ng/ml, 1h) 
profoundly induced expression of IFN-γ and IL-2, and pre-incubation of these cells with 
fludarabine (2.5 μM, 3 hrs) decreased TNF-α-stimulated expression of either IFN-γ and 
IL-2 by approximately 90 % and 80 %, respectively, as measured by real-time PCR 
(Figure 5a, b). Likewise, fludarabine decreased cytokine-stimulated production of 
TNF-α in PBMCs (Figure 5c, d).
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Discussion 
Fludarabine has been used for treatment of B-cell malignancies such as chronic 
lymphocytic leukemia. Fludarabine induced apoptosis of malignant B-cells.19 We have 
recently shown that fludarabine was also active against T-cell malignancies; fludarabine 
induced growth arrest and apoptosis of adult T-cell leukemia (ATL) cells. We found that 
NF-B abberantly expressed in nucleus in ATL cells. Exposure of ATL cells to 
fludarabine inhibited nuclear accumulation of NF-κB and downregulated levels of 
NF-κB-target molecule XIAP, which is a member of inhibitor of apoptosis proteins, in 
these cells. 20 
 Similarly, this study demonstrated that fludarabine blocked TNF-α-induced 
nuclear translocation of NF-κB in Jurkat T-cells, resulting in inactivation of this 
prosurvival nuclear transcription factor. As expected, fludarabine inhibited cytokine-, as 
well as alloantigen-stimulated proliferation of PBMCs in conjunction with decreased in 
production of Th1 cytokines such as IL-2 and IFN-γ. IL-2 is secreted by donor CD4+ T 
cells in the first several days after on-set of GVHD induction, 21 and induces cytotoxic 
T-lymphocyte (CTL) response. Monoclonal antibodies against IL-2 or its receptor was 
able to prevent GVHD when administered shortly after the infusion of T cells. 22, 23 In 
addition, both of cyclosporine and FK506, an immunosuppressive agent, dramatically 
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reduced IL-2 production and effectively prevent GVHD. 24 IFN-γ is also crucial cytokine 
in the second step of the pathophysiology of acute GVHD, which primes mononuclear 
phagocytes to produce TNF-α and IL-1. High IFN-γ levels were associated with acute 
GVHD, 25-27 and a large proportion of T-cell clones isolated from GVHD patients 
produced IFN-γ. 28 Thus, inhibition of production of IL-2 and IFN-γ may alleviate 
severity of acute GVHD. 
Another nucleoside analogue cytarabine also inhibited the proliferation of 
TNF-α or PHA-stimulated proliferation of PBMCs (Figures 3d, e); however, cytarabine 
did not affect TNF-α induced nuclear translocation of NF-κB in Jurkat cells (Figure 1c). 
These observations suggested that inhibition of NF-κB was not universal among 
nucleoside analogues.     
Taken together, fludarabine acts as an immunosuppressive agent via inhibition of 
NF-κB. Further studies are warranted to evaluate the effect of fludarabine in 
inflammatory diseases including GVHD. 
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Figure legends 
Figure 1. Effect of fludarabine on TNF-α induced phosphorylation and 
degradation of IκB (a) and nuclear translocation of NF-κB (b), (c) in Jurkat cells. 
Jurkat cells were pretreated with either fludarabine (2.5 μM) or diluent for 3hrs. At the 
end of the treatment, cells were washed twice with PBS and exposed to TNF-α (20 
ng/ml) for the indicated time periods. The cytoplasmic (a) and nuclear extracts (b) of 
these cells were prepared and subjected to Western blot analysis to measure the level of 
IκBα and phospho-IκBα, and p65 of NF-κB, respectively. (c) Immunocytochemistry. 
Jurkat cells were cultured either with or without fludarabine (2.5 μM) or cytarabine (2.5 
μM) for 3 hrs. At the end of the treatment, cells were exposed to TNF-α (20 ng/ml) for 
15 min. Cells were harvested and cytocentrifuge slides were prepared. Anti-NF-κB and 
anti-mouse IgG antibodies were used and immune complexes were visualized using the 
LSAB2 system. Sections were counterstained with hematoxylin. 
Figure 2. Effect of fludarabine on TNF-a-stimulated NF-kB/DNA binding 
formation in Jurkat cells. Jurkat cells were pretreated with either fludarabine (2.5 
mM) or diluent for 3h. At the end of the treatment, cells were washed twice with 
phosphate-buffered saline and exposed to TNF-α (20 ng/ml) for 60 min. Nuclear 
extracts were prepared and electrophoretic mobility shift assay was performed as 
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described in Materials and methods. The arrow indicates the gel location of NF-κB 
bound to DNA. WT, wildtype oligonucleotide; mt, mutant oligonucleotide; TNF-α, 
tumor necrosis factor a; NF-κB, nuclear factor κB. 
Figure 3. Fludarabine inhibits the proliferation of TNF-α- (a, d), PHA- (b, e), or 
alloantigen- (c) stimulated PBMCs. PBMCs from healthy volunteers were cultured 
with/without TNF-α (20 ng/ml) (a, d) or PHA (5 μg/ml) (b, e) in the presence or 
absence of various concentrations of fludarabine (0.5-5 μM) (a, b) or cytarabine (d, e). 
(c) PBMCs were cocultured with irradiated (3 Gy) allogeneic PBMCs and exposed to 
various concentrations of fludarabine (0.5-5 μM). Cell viability was assed by MTT 
assay on day 3 of culture. Results represent the mean ± SD of three experiments done in 
triplicate. Statistical analysis was performed by one-way ANOVA followed by 
Boneferroni’s multiple comparison tests. 
Figure 4. Fludarabine induces apoptosis of activated T cells. (a) TNF-α-stimulated 
PBMCs (1 x 106 /ml) were cultured with/without fludarabine. The ability of fludarabine 
to induce apoptosis was assessed by propidium idodide (PI) and annexin V staining. 
Lower left quadrants; viable cells (Annexin V- / PI-). Lower right quadrants; early 
apoptotic cells (Annexin V+/ PI-). Upper left quadrants; necrotic cells (Annexin V- / 
PI+). Upper right quadrants; late apoptotic cells (Annexin V+ / PI+). The result shows 
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one of the representative experiments performed three times independently. Flu, 
Fludarabine. (b) Western blot analysis of activated caspase (cleaved PARP) in 
PBMCs. TNF-α-stimulated PBMCs (1 x 106 /ml) were cultured with/without 
fludarabine (2.5 or 5 μM). After 24hrs, cells were harvested, and proteins were extracted 
and subjected to Western blot analysis. The membranes were sequentially proved with 
anti-PARP and anti-α-tubulin antibodies. 
Figure 5. Effect of fludarabine on TNF-α-stimulated cytokine expression in Jurkat 
cells. (a, b) Jurkat cells and (c, d) PBMCs were pretreated with either fludarabine (2.5 
μM) or diluent for 3 hrs. At the end of the treatment, cells were washed twice with PBS 
and treated with TNF-α (20 ng/ml) for 1h. Cells were harvested and RNA was extracted. 
cDNAs were synthesized and subjected to real-time PCR by using SYBY Green I 
nucleic acid gel staining solution. Results represent the mean ± SD. Statistical analysis 
was performed by one-way ANOVA followed by Boneferroni’s multiple comparison 
test. Flu, Fludarabine. 
  
Table 1. PCR primers. 
                                                                    
Protein        Direction              Primer                           
IL-2  Forward  5’-TGCAACTCCTGTCTTGCATT-3’ 
  Reverse  5’-TCCAGCAGTAAATGCTCCAG-3’ 
IFN-γ  Forward  5’-TCATCCAAGTGATGGCTGAA-3’ 
  Reverse  5’-CTTCGACCTCGAAACAGCAT-3’ 
18S  Forward  5’-AAACGGCTACCACATCCAAG-3’ 
  Reverse  5’-CCTCCAATGGATCCTCGTTA-3’        
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